Patients positive for VEGFR2 were confirmed to have higher serum AFP levels, larger tumor dimensions on ceMRI, higher LI-RADS scores, and larger tumor dimensions on final pathology (all p<0.001). This evidence concerns the gene AFP and neoplasm.